# Acrivon Therapeutics (ACRV) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ACRV
## Company Profile
- Ticker: ACRV
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 1.72 USD
- Market cap: 67198714.53 USD
- Last updated: 2026-08-12
## Business Overview
### Generative Phosphoproteomics Platform
Acrivon Therapeutics uses its AP3 platform to measure drug-regulated signaling inside intact cells and identify tumors most likely to respond to specific medicines.
### ACR-368
ACR-368 is a CHK1/2 inhibitor in a registrational-intent Phase 2b study, with increasing focus on serous endometrial cancer and development both with and without biomarker-based patient selection.
### ACR-2316
ACR-2316 is a dual WEE1 and PKMYT1 inhibitor designed through the AP3 platform. Early clinical development is prioritizing tumor types predicted to depend on the targeted cell-cycle pathways.
## Why The Stock Is Moving

The latest monitored company update is “Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- A simultaneous interim analysis and data update from both all-comer serous endometrial cancer arms of the ACR-368 Phase 2b study are expected in the second half of 2026.
- Acrivon expects readiness for a Phase 3 confirmatory study of ACR-368 with PD-1 therapy by mid-2026.

## Drug Assets

- ACR-368

## Recent News
- 2026-08-12 20:05 EST — [Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts](https://biopharmsignal.com/news/ACRV/acrivon-reports-second-quarter-2026-financial-results-and-highlights-upcoming-20-d57ea2e3) — Source: Acrivon Therapeutics
- 2026-08-05 12:30 EST — [Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study](https://biopharmsignal.com/news/ACRV/acrivon-advances-acr-2316-a-potential-first-in-class-wee1-pkmyt1-inhibitor-into--fc7c1501) — Source: Acrivon Therapeutics
- 2026-07-21 20:30 EST — [Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference](https://biopharmsignal.com/news/ACRV/acrivon-to-highlight-the-power-of-its-ap3-platform-for-streamlined-pathway-based-9df593ea) — Source: Acrivon Therapeutics
- 2026-05-21 11:30 EST — [Acrivon Therapeutics to Present at TD Cowen’s 7th Annual Oncology Innovation Summit](https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-to-present-at-td-cowen-s-7th-annual-oncology-innovation-summit) — Source: Acrivon Therapeutics
- 2026-05-15 20:00 EST — [Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/ACRV/acrivon-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-9a263134) — Source: Acrivon Therapeutics